Abstract

There is provided a recombinant clotting factor X protein with a serine protease catalytic domain having at least 90 % sequence identity to SEQ ID NO:6 while still retaining X136, and wherein X is Q, G, A, V, P, S, N, F, Y, C, T, M, L, W, I, E or D. There is also provided a pharmaceutical composition containing the recombinant clotting factor X protein. The recombinant is useful for dissolving a blood clot in a subject in need thereof, reducing coagulation in a subject in need thereof, and/or treating heart attack, stroke, pulmonary embolism or deep vein thrombosis in a subject in need thereof.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation. (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cells donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness.

Abstract

There is provided an antibody or a fragment thereof comprising six complementarity-determining regions (CDRs) having the sequences of SEQ ID Nos: 1, 2, 3, 4, 5 and 6 as described herein. The antibody or fragment thereof is useful for treating, limiting, or avoiding the activation of an immune cell caused by IgG antibodies bridging FcγRIIIA with HLA, and/or HPA-1a.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present disclosure concerns the use of agents to increase the size of a population of normal hematopoietic stem and progenitor cells (HSPCs) outside of the body. The present disclosure also concerns the therapeutic use of a population of normal HSPCs, where the population size has been increased by the use of the agents. The present disclosure also concerns a kit that contains agents that can be use to increase the size of a population of normal HSPCs outside of the body.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Abstract

12344 are as defined herein.

IPC Classes  ?

• C07D 231/16 - Halogen atoms or nitro radicals
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present disclosure concerns the use of agents to increase the size of a population of normal hematopoietic stem and progenitor cells (HSPCs) outside of the body. The present disclosure also concerns the therapeutic use of a population of normal HSPCs, where the population size has been increased by the use of the agents. The present disclosure also concerns a kit that contains agents that can be use to increase the size of a population of normal HSPCs outside of the body.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/078 - Cells from blood or from the immune system

Abstract

There is provided a method of sampling an aliquot of blood products from a main container containing the blood products to be sampled. The method includes providing a sample container that is rectangular-shaped and has a length-over−width (L/W) ratio of at least that of the main container, and fluidly connecting the a sample container to the main container, transferring the aliquot of the blood products from the main container to the sample container, and forming an air bubble in the sample container by introducing a volume of air into the sample container with the aliquot of the blood products. The volume of air forming the air bubble corresponds to at least about 5% of a volume of the aliquot of the blood products. A sampling bag and a sampling system are disclosed.

IPC Classes  ?

• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

The invention relates to an antibody to a red blood cell for use in treating or preventing an inflammatory disorder, and to methods of treating or preventing an inflammatory disorder comprising administering to a subject in need thereof a therapeutically effective amount of an antibody to a red blood cell.

IPC Classes  ?

• C07K 16/34 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

There is provided a method of sampling an aliquot of blood products from a main container containing the blood products to be sampled. The method includes providing a sample container that is rectangular-shaped and has a length-over- width (L/W) ratio of at least that of the main container, and fluidly connecting the a sample container to the main container, transferring the aliquot of the blood products from the main container to the sample container, and forming an air bubble in the sample container by introducing a volume of air into the sample container with the aliquot of the blood products. The volume of air forming the air bubble corresponds to at least about 5% of a volume of the aliquot of the blood products. A sampling bag and a sampling system are disclosed.

IPC Classes  ?

• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• B65D 30/10 - Sacks, bags or like containers characterised by shape or construction
• B65D 33/36 - Means for discharging contents
• G01N 1/20 - Devices for withdrawing samples in the liquid or fluent state for flowing or falling materials

Abstract

The invention relates to an antibody to a red blood cell for use in treating or preventing an inflammatory disorder, and to methods of treating or preventing an inflammatory disorder comprising administering to a subject in need thereof a therapeutically effective amount of an antibody to a red blood cell.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/34 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cell donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness

Abstract

The present disclosure relates to a compound of formula or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

IPC Classes  ?

• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/20 - One oxygen atom attached in position 3 or 5
• C07D 231/22 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
• C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation. (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cell donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation. (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cell donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cell donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood and plasma donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products; Recruitment, collection, testing, manufacture and distribution of cord blood stem cells; research in the field of stem cells; recruitment adult stem cell donors; searching for matched unrelated stem cell donors; coordinating stem cell collection, delivery and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors; coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; providing advice, education, and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks; research and development in the field of organ and tissue donation and transplantation.

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood and plasma donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products; Recruitment, collection, testing, manufacture and distribution of cord blood stem cells; research in the field of stem cells; recruitment adult stem cell donors; searching for matched unrelated stem cell donors; coordinating stem cell collection, delivery and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors; coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; providing advice, education, and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks; research and development in the field of organ and tissue donation and transplantation.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks for business management; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells (4) Providing professional and public education on blood, blood products, blood testing and blood typing; providing education in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; research and development in the field of organ and tissue donation and transplantation; providing scientific information on blood, blood products, blood testing and blood typing (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; coordinating stem cell collection and transplantation with national and international transplant centres and registries; collection and testing of blood and blood products and alternatives for medical purposes; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness; post-donation follow-up with stem cell donors for medical purposes; providing medical information on blood, blood products, blood testing and blood typing; providing advice and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation to promote public awareness

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood and plasma donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products; Recruitment, collection, testing, manufacture and distribution of cord blood stem cells; research in the field of stem cells; recruitment adult stem cell donors; searching for matched unrelated stem cell donors; coordinating stem cell collection, delivery and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors; coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; providing advice, education, and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks; research and development in the field of organ and tissue donation and transplantation.

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood and plasma donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products; Recruitment, collection, testing, manufacture and distribution of cord blood stem cells; research in the field of stem cells; recruitment adult stem cell donors; searching for matched unrelated stem cell donors; coordinating stem cell collection, delivery and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors; coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; providing advice, education, and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks; research and development in the field of organ and tissue donation and transplantation.

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood and plasma donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products; Recruitment, collection, testing, manufacture and distribution of cord blood stem cells; research in the field of stem cells; recruitment adult stem cell donors; searching for matched unrelated stem cell donors; coordinating stem cell collection, delivery and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors; coordinating the exchange of information between stem cell donors and recipients; Organizing, operating and managing an interprovincial system for organ donation and transplantation, namely a national transplant registry comprising a national organ waitlist, a living donor pairing and transplant program, a hard-to-match organ recipient program and a specific organ donor match allocation program; raising and promoting public awareness for organ and tissue donation; providing advice, education, and direction in the development, implementation and evaluation of leading practices for organ and tissue donation and transplantation; analyzing and reporting on the interprovincial tissue and organ donation and transplant system performance metrics and benchmarks; research and development in the field of organ and tissue donation and transplantation.

Abstract

The present disclosure relates to monovalent antibodies and chimeric proteins (comprising the monovalent antibodies) for the treatment of an auto-immune inflammatory disorder or condition. The monovalent antibody moiety lacks a Fc region, is specific for an activating Fc receptor and is for limiting or avoiding the activation of an immune cell induced in the presence and upon the binding of a ligand of the activating Fc receptor to the activating Fc receptor. The monovalent antibodies and chimeric proteins are especially useful for the prevention, treatment or alleviation of symptoms associated with an auto-immune inflammatory disorder caused or maintained by the engagement of an auto-antibody having a Fc region capable of engaging the activating Fc receptor to mediate the pathological destructions of cells or tissues.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/44 - Antibodies bound to carriers
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/735 - Fc receptors
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 19/00 - Hybrid peptides

Abstract

This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/078 - Cells from blood or from the immune system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

IPC Classes  ?

• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 231/22 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
• C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
• C07D 231/20 - One oxygen atom attached in position 3 or 5
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/14 - BloodArtificial blood
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/14 - BloodArtificial blood
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/14 - BloodArtificial blood
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo- recognition. Acellular-based preparations and processes for achieving therapy are also provided.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 35/14 - BloodArtificial blood
• A61K 35/16 - Blood plasmaBlood serum
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.

IPC Classes  ?

• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C07D 207/452 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
• C12N 9/74 - Thrombin
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61K 38/49 - UrokinaseTissue plasminogen activator
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

IPC Classes  ?

• C07D 231/20 - One oxygen atom attached in position 3 or 5
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 5/078 - Cells from blood or from the immune system

Abstract

This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 35/14 - BloodArtificial blood
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Abstract

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

This invention relates to cellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population capable of proliferating. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 37/02 - Immunomodulators
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

There is described a sample holder and associated fluid container assembly for optical analysis of a fluid sample within a translucent container of the fluid container assembly. The sample holder includes clamping members rotatably mounted to a frame for rotation, about parallel axes spaced apart from each other, between a container accepting position in which the clamping members are spaced apart from the translucent container, and an analysis position in the clamping members abut the translucent container. The clamping members each define an optical waveguide slot extending therethrough that is substantially aligned with the translucent container when the clamping members are disposed in the analysis position, to thereby provide optical access to the translucent container for optical analysis of the fluid sample therein.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• F25B 29/00 - Combined heating and refrigeration systems, e.g. operating alternately or simultaneously
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light

Abstract

A deformable container (5) containing a fluid product to be tested includes a flexible outer wall (10) enclosing a main cavity (9) therein for holding the fluid product and at least one appendix (14) for containing a sample volume to be tested. The appendix is displaceable from a first position, wherein the appendix is invaginated within a periphery of the deformable container, and a second position, wherein the appendix protrudes outwardly from the outer wall and defines a second cavity (7) therein for a sample fluid volume, such as to permit testing of the sample volume within the appendix (14). The appendix is displaced into the second position by the fluid product within the deformable container when pressure is applied to the outer wall to force the sample volume of the fluid product from the main cavity of the deformable container into the second cavity of the appendix.

IPC Classes  ?

• G01N 1/00 - SamplingPreparing specimens for investigation
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B65D 1/00 - Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
• B65D 85/00 - Containers, packaging elements or packages, specially adapted for particular articles or materials
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 1/18 - Devices for withdrawing samples in the liquid or fluent state with provision for splitting samples into portions
• G01N 21/03 - Cuvette constructions
• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

A method of diagnosing a pathological condition by detecting microparticles in a sample of bodily fluid using dynamic light scattering (DLS) is disclosed. The detection of microparticles in the bodily fluid by DLS may be used as an indicator of existing disease, to evaluate a risk of disease, as well as to monitor the efficacy of a treatment for disease.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A01N 1/02 - Preservation of living parts

Abstract

The described apparatus for analyzing a biological sample includes a first analysis instrument fluidly connected to a reservoir for receiving a first flow of the biological fluid and adapted for performing a measurement of a property of the biological sample. A second analysis instrument is fluidly connected to the reservoir for receiving a second flow of the biological fluid and adapted for performing a thermally controlled analysis of the biological sample. The second analysis instrument includes a thermally controlled chamber. A flow stopping device stops the second flow within the thermally controlled chamber in order to allow the second analysis instrument to perform the thermally controlled analysis of the biological sample. The first analysis instrument may include, for example, a hematology analyzer or a flow cytometer, and the second analysis instrument may include, for example, a dynamic light scattering instrument.

IPC Classes  ?

• G01N 21/49 - Scattering, i.e. diffuse reflection within a body or fluid
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/06 - Investigating concentration of particle suspensions
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

Abstract

There is described a sample holder and associated fluid container assembly for optical analysis of a fluid sample within a translucent container of the fluid container assembly. The sample holder includes clamping members rotatably mounted to a frame for rotation, about parallel axes spaced apart from each other, between a container accepting position in which the clamping members are spaced apart from the translucent container, and an analysis position in the clamping members abut the translucent container. The clamping members each define an optical waveguide slot extending therethrough that is substantially aligned with the translucent container when the clamping members are disposed in the analysis position, to thereby provide optical access to the translucent container for optical analysis of the fluid sample therein.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation

Abstract

This application relates to agents capable of specifically recognizing GPIbα, a key receptor required for platelet adhesion and aggregation. More specifically, this application relates to monoclonal antibodies and derivatives thereof capable of specifically recognizing both the murine and the human GPIbα. These monoclonal antibodies and derivatives are particularly useful in the treatment or prevention of thrombosis as well as research tools.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

A method of diagnosing a pathological condition by detecting microparticles in a sample of bodily fluid using dynamic light scattering (DLS) is disclosed. The detection of microparticles in the bodily fluid by DLS may be used as an indicator of existing disease, to evaluate a risk of disease, as well as to monitor the efficacy of a treatment for disease.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/493 - Physical analysis of biological material of liquid biological material urine

Abstract

3 integrin fragments.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 20°C for at least one hour. After being stored, the at least one modified platelet may be introduced into a mammal.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

Methods of detecting bacterial contamination in a platelet concentrate are performed using a dynamic light scattering (DLS) instrument and a sample holder. A sample of platelet concentrate can be held vertically or horizontally in a capillary in the sample holder. Alternatively, novel platelet storage bags modified to include an optically translucent window can be held within another variant of the sample holder. Still alternatively, platelet storage bags having one or more tubes detachably appended to the bag can be used. A sample is drawn off into an appended tube for placement directly into the sample holder. This method provides a number of related, non- invasive techniques for detecting whether bacteria has contaminated a platelet concentrate. Contamination indicators include a population of particles different from platelets, microparticles or proteins, bad-quality platelets, i.e. low DLS score, and very high or very low scattering intensity.

IPC Classes  ?

• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• A61J 1/12 - Bag-type containers with means for holding samples of contents
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
• G01N 1/44 - Sample treatment involving radiation, e.g. heat
• G01N 15/02 - Investigating particle size or size distribution

Abstract

Mimotope receptors and inhibitors employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, such as liposomes, to act as synthetic platelets, for example, by providing binding sites for binding to other (natural or synthetic) platelets or to the endothelium. Synthetic platelets would have virtually limitless shelf life and would not require disease screening prior to transfusion, thereby providing a solution to the perpetual platelet shortages, as well as the safety and storage issues associated with natural blood platelets. Mimotope inhibitors (either free- molecule receptors or ligands) can act as antithrombotics by inhibiting platelet-platelet or platelet-endothelium interactions. Ligand mimics are preferably D-peptides that resist proteolytic degradation. Furthermore, these ligand mimics can also be attached to carriers for resisting excretion, thus forming the new class of antithrombotic drugs.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 35/14 - BloodArtificial blood
• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• C12N 5/06 -
• C12N 5/08 -

Abstract

A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone at one of the monomeric backbone units by a bond that is independently biodegradable or non-biodegradable. The chelation structure is synthesized by Radical Addition Fragmentation Transfer (RAFT), Atom Transfer Radical Polymerization (ATRP), or Free Radical Polymerization (FRP). The chelation structure, individually or in combination with a shuttle chelator, may be introduced into a mammal to bind an amount of a substance in a mammal, the substance being at least one of a metal and heme. The chelation structure has a log stability constant exceeding that of the shuttle chelator for binding the substance within cells of the mammal.

IPC Classes  ?

• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo

Goods & Services

(1) Recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; recruitment of cord blood stem cells. (2) Delivery of cord blood with national and international transplant centres and registries. (3) Coordinating sample collection and typing from stem cell donors; coordinating stem cell collection and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors for medical purposes.

Goods & Services

(1) Recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; public relations services for coordinating the exchange of information between stem cell donors and recipients; recruitment of cord blood stem cells. (2) Delivery of cord blood with national and international transplant centres and registries. (3) Coordinating sample collection and typing from stem cell donors; coordinating stem cell collection and transplantation with national and international transplant centres and registries; post-donation follow-up with stem cell donors for medical purposes.

Abstract

A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fcγ receptor-specific complex or a complex which results in the co-crosslinking of Fcγ-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fcγ receptor-specific complex and/or complex which results in the co-crosslinking of Fcγ-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing. (5) Research and development in the field of blood, blood products, blood testing and blood typing; provided scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; collection and testing of blood and blood products and alternatives for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing. (5) Research and development in the field of blood, blood products, blood testing and blood typing; provided scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; collection and testing of blood and blood products and alternatives for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing. (5) Research and development in the field of blood, blood products, blood testing and blood typing; provided scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; collection and testing of blood and blood products and alternatives for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood and plasma donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes. (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries. (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells. (4) Providing professional and public education on blood, blood products, blood testing and blood typing. (5) Research and development in the field of blood, blood products, blood testing and blood typing; provided scientific information on blood, blood products, blood testing and blood typing. (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; collection and testing of blood products and alternatives for medical purposes; providing medical information on blood, blood products, blood testing and blood typing.

Goods & Services

(1) Recruitment of blood, plasma and bone marrow donors; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; recruitment of adult stem cell donors; searching for matched unrelated stem cell donors; importation of blood and blood products and alternatives; recruitment of cord blood stem cells; distributorship of cord blood stem cells for medical purposes (2) Distribution of blood and blood products and alternatives; delivery of cord blood with national and international transplant centres and registries (3) Custom manufacture of blood and blood products and alternatives; custom manufacture of cord blood stem cells (4) Providing professional and public education on blood, blood products, blood testing and blood typing; (5) Research and development in the field of blood, blood products, blood testing and blood typing; research in the field of stem cells; provided scientific information on blood, blood products, blood testing and blood typing (6) Surveillance and monitoring of blood, blood products, blood testing and blood typing for medical purposes; providing critical practice guidelines for blood testing and blood typing for medical purposes; transfusion of blood and blood products; collection and testing of cord blood stem cells for medical purposes; collection and testing of blood and blood products and alternatives for medical purposes; providing medical information on blood, blood products, blood testing and blood typing

Abstract

There is provided a method for assessing the quality of platelet concentrates for determining their suitability for transfusion. More specifically dynamic light scattering measurements of the samples containing platelets are obtained and parameters, such as hydrodynamic radius and relative number of platelet-derived microparticles, are derived from these measurements that are indicative of platelet quality.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/14 - BloodArtificial blood

Goods & Services

(1) Collection, testing, manufacture, importation and distribution of blood and blood products and alternatives; recruitment of blood, plasma and bone marrow donors; research and development in the field of blood, blood products, blood testing and blood typing; surveillance and monitoring of blood, blood products, blood testing and blood typing; providing professional and public education and information on blood, blood products, blood testing and blood typing; data management services, namely, tracking the collection, processing, distribution and utilization of blood and blood products; providing critical practice guidelines for blood testing and blood typing; transfusion of blood and blood products.

Goods & Services

(1) Scientific research equipment for testing deoxyribonucleic acid (DNA).

Goods & Services

(1) Operation of a blood-donor service, namely the distribution of blood. (2) Operation of a blood-donor service, namely the collection, storage, and distribution of blood.

Goods & Services

(1) Operation of a blood-donor service, namely the distribution of blood (2) Operation of a blood-donor service, namely the collection, storage, and distribution of blood.

Goods & Services

(1) Operation of a blood-donor service, namely the distribution of blood. (2) Operation of a blood-donor service, namely the collection and storage of blood.

Goods & Services

(1) Operation of a blood-donor service, namely the distribution of blood. (2) Operation of a blood-donor service, namely the collection and storage of blood.